The MarketWatch News Department was not involved in the creation of this content.-- New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-bur ...

New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatment; All six patients responded positively ...

The Utah Department of Health and Human Services has reported 87 cases of measles, with most of those cases occurring in ...

Company to present 40-week topline results from the Phase 2 study of migaldendranib (MGB), a first-in-class subcutaneous nanomedicine, being developed for the treatment of DME and nAMD FDA alignment ...

What if instead of temporarily relieving your allergies with medication, you could train your immune system to stop overreacting to your allergens altogether? That's the idea behind ...

If you're a new investor and tend to gravitate toward growth stocks, there are plenty of compelling buys to consider in the ...

MSU professor Melanie Balbach wrote a paper recently published in Proceedings of the National Academy of Sciences, where her ...

Kidney disease disproportionately affects Black communities, with Black Americans nearly four times as likely to develop ...

November is Diabetes Awareness Month, and on this week's Health Matters, WVUA 23 News sat down with University Medical Center ...

Your wedding countdown starts now! Find the Top five expert-approved bridal skin treatments and procedures to achieve that ...

At the next visit, his wife asked me about the potential causes of chronic inflammation that she’d read about online—tick bites, heavy-metal exposures, nutritional deficiencies—as well as ...

Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsIlan Sobel - Chief Executive OfficerBar Dichter ...